The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRAS G12C Mutation
Open accessAbstract
BACKGROUND: , locking it in its inactive state. Adagrasib showed clinical activity and had an acceptable adverse-event profile in the phase 1-1b part of the KRYSTAL-1 phase 1-2 study. METHODS: -mutated non-small-cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy and anti-programmed death 1 or programmed death ligand 1 therapy. The primary end point was objective response assessed by blinded independent central review. Secondary end points included the duration of response, progression-free survival, overall survival, and safety. RESULTS: -mutated NSCLC had been treated (median follow-up, 12.9 months); 98.3% had previously received both chemotherapy and immunotherapy. Of 112 patients with measurable disease at baseline, 48 (42.9%) had a confirmed objective response. The median duration of response was 8.5 months (95% confidence interval [CI], 6.2 to 13.8), and the median progression-free survival was 6.5 months (95% CI, 4.7 to 8.4). As of January 15, 2022 (median follow-up, 15.6 months), the median overall survival was 12.6 months (95% CI, 9.2 to 19.2). Among 33 patients with previously treated, stable central nervous system metastases, the intracranial confirmed objective response rate was 33.3% (95% CI, 18.0 to 51.8). Treatment-related adverse events occurred in 97.4% of the patients - grade 1 or 2 in 52.6% and grade 3 or higher in 44.8% (including two grade 5 events) - and resulted in drug discontinuation in 6.9% of patients. CONCLUSIONS: -mutated NSCLC, adagrasib showed clinical efficacy without new safety signals. (Funded by Mirati Therapeutics; ClinicalTrials.gov number, NCT03785249.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These results indicate the rapid development of acquired resistance to KRAS G12C inhibitors [18, 26, 27, 49].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The data from both CodeBreak 100 for sotorasib and KRYSTAL-1 for adagrasib led to the approval of these inhibitors to treat G12C-mutant NSCLC [51,53,94].”
From KRAS: Biology, Inhibition, and Mechanisms of Inhibitor Resistance (2024) · cites this paper as [94]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In clinical trials, the inactive-state KRASG12C mutant-specific inhibitors adagrasib (MRTX849) and sotorasib (AMG510) achieved 37–43% anti-tumor response rates in NSCLC patients with most experiencing disease progression 6–12 months after initiation of therapy7–9.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“STK11/LKB1 loss and KEAP1 mutations may contribute to lack of response to different therapies including anti-PD-(L)1 immune checkpoint inhibitors9,10 and KRASG12C inhibitors3,4.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For adagrasib, an ORR was 23.0% in CRC, compared to 42.8% in NSCLC (Table 1) [27, 48].”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Colorectal cancer, in particular, has a markedly lower response rate to KRAS G12C inhibitors compared to non-small cell lung cancer.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the therapeutic response to KRAS G12C inhibition was short-lived, with quick emergence of acquired resistance.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Even in NSCLC patients, the response to KRAS G12C inhibitors was often short-lived, with a DOR of 10.9–11.1 months and PFS of 6.3–6.8 months for sotorasib, and a DOR of 8.5 months and PFS of 6.5 months for adagrasib (Table 1).”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, sotorasib, adagrasib, and divarasib monotherapies have demonstrated objective response rates ranging from 7.1% to 53.4% and median progression-free survival of 4.0-13.1 months, 13-20”
From Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The overall response rate of inactive-state KRASG12C inhibitors sotorasib and adagrasib in patients with KRASG12C mutant NSCLC is 37-43%, a major advance albeit with significant room for improvement7,8.”
From Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer (2024) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“This is further supported by a numerically higher ORR seen with divarasib in patients with non-small cell lung cancer (56.4%) compared with sotorasib (37% in a phase 2 trial and 28% in a phase 3 trial) and adagrasib (43% in a phase 2 trial)11,23–25.”
From Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial (2024) · cites this paper as [24]
The cited source says what the claim attributes to it.
In the citing paper
“Clinical studies have shown that many patients with KRAS G12C cancers did not respond to sotorasib and adagrasib.”
From Differential Response and Resistance to KRAS-Targeted Therapy (2025) · cites this paper as [27]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Because KRAS mutations are often clonal founder events, mutant KRAS ctDNA can serve as a highly informative molecular marker for tumor burden, treatment response, minimal residual disease, and emergence of resistance [29,47,77,78].”
From Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies (2026) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective, irreversible inhibitor of KRASG12C and has favorable properties, including long half-life (23 hours), dose-dependent pharmacokinetics, and central nervous system penetration (3–5).”
From Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer (2024) · cites this paper as [4]
In the citing paper
“Adagrasib is a selective and irreversible oral small-molecule inhibitor of the mutant KRAS G12C protein18 and was recently approved by the FDA for treatment of NSCLC who have received at least 1 prior systemic therapy19.”
From Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients (2023) · cites this paper as [19]
In the citing paper
“This subset of patients that were evaluable for longitudinal KRASG12C ctDNA response in Cohort A exhibited a slightly higher ORR (56.4%, 22/39 cycle ctDNA response evaluable) compared to Cohort A overall (50.5%, 48/95 RECIST 1.1 evaluable patients)19”
From Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients (2023) · cites this paper as [19]
In the citing paper
“Updated data from 116 patients with previously treated NSCLC included in a registrational phase II cohort of KRYSTAL-1 showed an ORR of 42.9%, a DCR of 79.5%, median DoR of 8.5 months, median PFS of 6.5 months, median OS of 12.6 months and estimated 1-year OS of 50.8% with adagrasib83.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [83]
In the citing paper
“While these drugs clearly have clinical activity, overall response rates (30-40%) and disease control (~60%) in NSCLC are modest and transient, with median duration less than one year (9,10).”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [10]
In the citing paper
“Multiple mechanisms of intrinsic and acquired resistance (10,12,13), have been identified; hence, drug combinations will likely be needed to maximize the clinical efficacy of G12Cis (and probably other, emerging KRAS inhibitors) in NSCLC and other diseases.”
From Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy (2023) · cites this paper as [10]
In the citing paper
“The phase II portion of KRYSTAL-2 included 116 patients with KRAS G12C NSCLC treated with adagrasib 600 mg bid [100]. All patients had prior platinum-doublet chemotherapy and 98.3% had received both chemotherapy and checkpoint inhibitor therapy. With a median follow-up of 12.9 months, the ORR was 42.9%.”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [100]
In the citing paper
“Among 33 patients with previously treated, stable central nervous system metastases, the intracranial confirmed objective response rate was 33.3% (95% CI, 18.0–51.8) [100].”
From Drugging KRAS: Current perspectives and state-of-art review (2022) · cites this paper as [100]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Sotorasib for Lung Cancers with KRAS p.G12C Mutation
Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., Italiano, A., Schuler, M., Borghaei, H., Barlesi, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103695 · Cited by 1,849
Self-citationGaron, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Hallin, J., Engstrom, L. D., Hargis, L., Calinisan, A., Aranda, R., Briere, D. M., Sudhakar, N., Bowcut, V., Baer, B. R., Ballard, J. A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1167 · Cited by 1,304
Self-citationAllele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691
Fell, J. B., Fischer, J. P., Baer, B. R., Blake, J. F., Bouhana, K., Briere, D. M., Brown, K. D., Burgess, L. E., Burns, A. C., Burkard, M. R., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02052 · Cited by 653
Self-citationRapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
Xue, J. Y., Zhao, Y., Aronowitz, J., Mai, T. T., Vides, A., Qeriqi, B., Kim, D., Li, C., de Stanchina, E., Mazutis, L., et al. (2020) · Nature · doi:10.1038/s41586-019-1884-x · Cited by 543
Mehta, M. P., Rodrigus, P. T. R., Terhaard, C. H. J., Rao, A. R., Suh, J. H., Roa, W., Souhami, L., Bezjak, A., Leibenhaut, M. H., Komaki, R. U., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.122 · Cited by 466
Targeting the untargetable KRAS in cancer therapy
Liu, P., Wang, Y., & Li, X. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.002 · Cited by 366
Flagged first, then by citations
Research works printed but not linked: 1
- Mirati Therapeutics. U.S. Food and Drug Administration (FDA) accepts Mirati Therapeutics’ new drug application for adagrasib as treatment of previously treated KRASG12C-mutated non-small cell lung cancer. February 15 2022 (https://ir.mirati.com/press-releases/press-release-details/2022/U.S.-Food-and-Drug-Administration-FDA-Accepts-Mirati-Therapeutics-New-Drug-Application-for-Adagrasib-as-Treatment-of-Previously-Treated-KRASG12C-Mutated-Non-Small-Cell-Lung-Cancer/default.aspx).
Cited by
Sorted by citations
Items 601–700 of 1,002
THE ROLE OF NEXT-GENERATION SEQUENCING IN LUNG CANCER DIAGNOSIS
Moskalenko, J., Vynnychenko, О. І., Sulaieva, O., & Moskalenko, R. (2023) · Eastern Ukrainian Medical Journal · doi:10.21272/eumj.2023;11(3):214-223 · Cited by 3
Hamilton, G., Stickler, S., & Rath, B. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00178 · Cited by 3
Leung, J. C., Xu, Y., Radomkit, S., Lee, J., Kim, W. S., Reeves, J. T., Dong, W., Jang, H., Hou, X., Lorenz, J. C., et al. (2024) · Organic Process Research & Development · doi:10.1021/acs.oprd.3c00362 · Cited by 3
“New Targets in Non–Small-Cell Lung Cancer”—RET, HER2, and KRAS
HALANI, V., Sharayah, A. M., Beck, B., & Patolia, S. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202208-1596rr · Cited by 3
Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer
Karachaliou, A., Kotteas, E. A., Fiste, O., & Syrigos, K. (2024) · Cancers · doi:10.3390/cancers16081447 · Cited by 3
Giglio, A. D., Zacchini, F., Venturi, G., Federico, A. D., Parisi, C., Dall’Olio, F. G., Ricciotti, I., Favorito, V., Gagliano, A., de Biase, D., et al. (2024) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2024.100161 · Cited by 3
Choi, D.-H., Jang, H., Lim, S. H., Kim, S. T., Hong, J. Y., Park, S. H., Park, J. O., Kim, D. G., Kim, K., & Lee, J. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155473 · Cited by 3
Liang, J., Huang, J., Yang, J., Liang, W., Li, H., Wu, Y., & Liu, B. (2024) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2024.2390911 · Cited by 3
Machine learning approach to assess brain metastatic burden in preclinical models
Rappaport, J., Chen, Q., McGuire, T., Lopès, A., & Goldszmid, R. S. (2024) · Methods in cell biology · doi:10.1016/bs.mcb.2024.10.001 · Cited by 3
Vitale, A., Vita, E., Stefani, A., Cancellieri, A., Lococo, F., Tortora, G., & Bria, E. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf030 · Cited by 3
The Role of RAS in CNS Tumors: A Key Player or an Overlooked Oncogene?
Barbosa, I. D. S., Heming, C. P., Moura‐Neto, V., & Aran, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094104 · Cited by 3
A panorama of lung cancer biomarkers
Mesquita, A. S. S., Maeda, M. I., Brandão, J. C. D., Gaglionone, N. C., da Silva, I. C., Mak, M. P., & do Nascimento, É. C. T. (2025) · Surgical and Experimental Pathology · doi:10.1186/s42047-025-00177-5 · Cited by 3
Bispecific T cell engagers kill resistant cells during KRAS-G12C blockade therapy
Song, X., Zhou, Z., Kang, R., & Tang, D. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2141978 · Cited by 3
Redding, A., & Grabocka, E. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1304 · Cited by 3
Desai, A. P., & Dimou, A. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.07.013 · Cited by 3
Popescu, B., Jones, M. F., Piao, M., Tran, E., Koh, A., Lomeli, I., Peretz, C. A. C., Murad, N. F., Abelson, S., Morales, C., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.10.658786 · Cited by 3
Molecular Testing in Lung Cancer
Borczuk, A. (2023) · Surgical pathology clinics · doi:10.1016/j.path.2023.11.012 · Cited by 2
KRAS inhibitors in drug resistance and potential for combination therapy
Rathod, L. S., Sakle, N. S., & Mokale, S. N. (2024) · Tumori Journal · doi:10.1177/03008916241289206 · Cited by 3
Zhang, Y., Ma, Y., Zhang, K., Wang, Y., Sun, X., Kan, C., & Han, F. (2025) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001192 · Cited by 2
Provenzano, D., Lichtenberger, J. P., Goyal, S., & Rao, Y. J. (2025) · Applied Sciences · doi:10.3390/app15074053 · Cited by 3
Zhang, Y., Tong, S., & Wan, L. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2499219 · Cited by 2
Bhatt, A., Yone, N., Lalla, M., Jeon, H., & Cheng, H. (2025) · Cancers · doi:10.3390/cancers17121950 · Cited by 3
McDonald, R. A., Varela-Ramı́rez, A., & Ashley, A. K. (2025) · Biology · doi:10.3390/biology14080936 · Cited by 2
Novel paradigms in KRAS targeting: Unveiling strategies to combat drug resistance
Luo, X., Zhou, F., Tang, Y., Liu, X., Xiao, R., Gu, M., Bai, J., Jiang, D., Yang, G., You, L., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003776 · Cited by 2
Clinical Outcomes and Safety Profile of Adagrasib in KRAS G12C-Mutated Solid Tumors
Ahmad, O., Rath, S., Banatwala, U. E. S. S., Alam, U., Islam, M. R., Wahid, A., Sajjad, F., Khan, W. F., & Gain, A. (2025) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000001249 · Cited by 3
Manolakos, P., Wang, Y.-B., Withycombe, J. S., Boccuto, L., & Ivankovic, D. S. (2025) · Biomedicines · doi:10.3390/biomedicines13092142 · Cited by 2
Emerging Systemic Therapy Considerations for Pancreatic Cancer
Liang, K.-L., Guo, M. Z., & Zaidi, N. (2025) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2025.07.006 · Cited by 2
Functional Analysis of Rare RAS Variants of Unknown Significance
Park, S., Ikegami, M., Kitada, R., Takamochi, K., Suzuki, K., Mano, H., & Kohsaka, S. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-25-0188 · Cited by 3
Yang, H., Zhu, A., Niu, Y., Ma, W., Xu, K., Jia, Y., Xu, W., Zhao, B., Zhang, E., Jia, J., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70490 · Cited by 2
Proteomic Perspectives on KRAS-Driven Cancers and Emerging Therapeutic Approaches
Karki, R., Chen, R., & Pan, S. (2025) · Current Oncology · doi:10.3390/curroncol32110614 · Cited by 3
Terasaki, F., Kumagai, S., Fukuda, A., Tanaka, Y., Irie, T., Ito, S., Yamada, M., Onoe, S., Mizuno, T., Kokuryo, T., et al. (2025) · International Immunology · doi:10.1093/intimm/dxaf065 · Cited by 2
Emerging biomarkers for early detection of lung cancer
Khangar, P. K., Daniel, V., Vengurlekar, S., Daniel, K., & Jain, S. K. (2025) · Clinical Cancer Bulletin · doi:10.1007/s44272-025-00046-y · Cited by 2
Tumor suppressor genes and KRAS G12C inhibitor resistance in non-small cell lung cancer
Zhu, L., Jia, X., Xu, L., Chen, L., Fu, X., Yan, H., Ai, B., & Peng, S. (2025) · iScience · doi:10.1016/j.isci.2025.114429 · Cited by 2
Development of Scalable Synthesis of RAS Inhibitor’s Indole Building Block via Flow Chemistry
Debnath, S., Wang, W., Xue, S., Mondal, S., & Zhu, X. (2025) · Organic Process Research & Development · doi:10.1021/acs.oprd.5c00350 · Cited by 2
The evolving landscape of KRAS-targeted therapy: mechanisms of resistance and emerging strategies
Pilco‐Janeta, D. F., & Puebla, M. D. L. C. (2025) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001801 · Cited by 2
Zhao, S., Liu, X., Tan, P., Mu, Y., Tan, S., & Hou, A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1747371 · Cited by 2
Mankuzhy, N. P., Santo, V., Shin, J. Y., Chaunzwa, T. L., Gelblum, D. Y., Wu, A. J.-C., McMillan, M. T., Ma, J., Billing, D. L., Iyengar, P., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103565 · Cited by 2
Ovejero, L. D. L. P., Fernández-Rodríguez, A., Francoz, S., Aizpurua, G., Lomba-Riego, L., Drosten, M., Guerra, C., Musteanu, M., Barbacid, M., & García‐Alonso, S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0341778 · Cited by 1
Clinico-genomic characterization of RAS-mutant acute myeloid leukemia
Yuan, R., Xie, Y., Miron, P. M., Higgins, A. W., Hutchinson, L., Černý, J., & Patel, S. A. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06843-2 · Cited by 2
Delasos, L., & Hassan, K. A. (2026) · JCO Oncology Practice · doi:10.1200/op-25-01061 · Cited by 2
Stickler, S., Eggerstorfer, M.-T., Rieche, M., Arslan, S., Teufelsbauer, M., HOHENEGGER, M., Weigl, L. G., & Hamilton, G. (2026) · Scientific Reports · doi:10.1038/s41598-026-43207-2 · Cited by 3
Niranjan, N., Guan, T., Niranjan, N., Fard, A. T., Youlden, D. R., Mason, R., Chan, B. A., & Sanmugarajah, J. (2026) · Thoracic Cancer · doi:10.1111/1759-7714.70274 · Cited by 2
Protein exosites as drug targets: from structural topology to therapeutic modality
Omage, F. B., Mazoni, I., Yano, I. H., & Neshich, G. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104662 · Cited by 2
Peters, S., Hochmair, M. J., Arbour, K. C., Rodríguez, L. P.-A., Reck, M., Leal, T. A. B., Lindsay, C. R., Shun, L., William, W. N., Spira, A. I., et al. (2026) · Future Oncology · doi:10.1080/14796694.2026.2651961 · Cited by 2
Self-citationKamel, E. M., Khadrawy, S. M., Ali, M. A. M., Abukhadra, M. R., Yassin, N. Y. S., Alkhedhairi, S., Alkhayl, F. F. A., & Lamsabhi, A. M. (2026) · Frontiers in Chemistry · doi:10.3389/fchem.2026.1808601 · Cited by 3
Pastor, P. G., Gonzalez, N. S., Salvà, F., Ros, J., Baraibar, I., Rodríguez-Castells, M., de Torres, C. S., García, A., Alcaráz, A., Vaghi, C., et al. (2026) · Genes · doi:10.3390/genes17040460 · Cited by 2
Kawczak, P., & Bączek, T. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15083024 · Cited by 2
From G12C To pan-RAS: The expanding therapeutic landscape of KRAS-mutant NSCLC
Canaslan, K., Başbınar, Y., & Öztop, İ. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105344 · Cited by 2
Context-dependent synthetic lethality — an emerging precision therapeutic approach
Chang, L., Shaw, K. L., Vázquez, F., & Sellers, W. R. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00929-9 · Cited by 7
Mavrikios, A., Bortolot, M., Pechoux, C. L., Remón, J., Botticella, A., Aldea, M. D., Brown, P. D., Rusthoven, C. G., Lavaud, P., Frélaut, M., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.04.014 · Cited by 2
KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians
Remón, J., Cava, G. L., Borgeaud, M., Saw, S. P. L., Hendriks, L. E. L., & Ricciuti, B. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103144 · Cited by 3
Advances in targeted therapies for pediatric tumors
Liu, J.-Y., Yang, D.-L., Liu, H.-Y., Xiang, S.-F., Cao, J., Yang, B., He, Q.-J., Wang, J., Shao, X., & Ying, M.-D. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01805-w · Cited by 2
KRAS G12R in pancreatic cancer: why this mutation resists current inhibitor strategies
Kern, K. A. (2026) · The Oncologist · doi:10.1093/oncolo/oyag155 · Cited by 2
Khan, A., Imeh, M., Barad, P., & Rosas, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135883 · Cited by 2
Song, Z., Li, X., Lin, R., Shi, H., Yuan, Y., Liu, Y., Luo, Y., Lv, T., Zhang, Y., Zhu, L., et al. (2026) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(26)00142-6 · Cited by 2
Shaik, M. N., Yerrakula, G., Raghunathachar, S. K., Bommareddy, D. A. J., Himavarshini, A., Kumar, B. K., Borra, S. S., & Bandaru, N. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04402-9 · Cited by 2
Clinical characteristics of patients with KRAS mutation detected by liquid biopsy
Amino, Y., Low, S., Ninomiya, H., Kiritani, A., Miyadera, K., Kakuto, S., Akita, T., Tsugitomi, R., Ariyasu, R., Uchibori, K., et al. (2023) · Thoracic Cancer · doi:10.1111/1759-7714.15123 · Cited by 2
Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers
O’Leary, C., Murphy, G., Yeung, Y., Tang, M., Jain, V. K. S., & O’Leary, C. G. (2023) · Cancers · doi:10.3390/cancers15235582 · Cited by 2
Xu, J., & Wang, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1285593 · Cited by 2
Rosell, R., Pedraz‐Valdunciel, C., Jain, A. S., Shivamallu, C., & Aguilar, A. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2320710 · Cited by 2
Sahu, P., Mitra, A., & Ganguly, A. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.01.005 · Cited by 2
Stratton, N. C., & Thompson, J. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100661 · Cited by 2
Fatima, S., Pansuriya, N., Lakhani, A., Madhuri, S., Ajmal, R., Clementina, R., Lakdawala, Z., Shah, K., Dilshana, H., Andrea, M., et al. (2024) · Cureus · doi:10.7759/cureus.60061 · Cited by 2
Li, J. J., Wu, X. J., Farzin, M., Bray, V., Williamson, J., Pal, A., Yip, P. Y., Hagelamin, A., Ding, P., Nindra, U., et al. (2024) · Pathology · doi:10.1016/j.pathol.2024.04.002 · Cited by 2
Mansour, N., Heinrich, K., Zhang, D., Winkelmann, M., Ingenerf, M., Gold, L., Klambauer, K., Rudelius, M., Klauschen, F., von Bergwelt‐Baildon, M., et al. (2024) · Cancer Imaging · doi:10.1186/s40644-024-00708-5 · Cited by 2
Aptekar, J. W., Jain, R., Korytowsky, B., Shafquat, A., Hendershot, J. M., Talwai, A., Itzkovich, Y., & Padda, S. K. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107854 · Cited by 2
Xu, Y., Li, M., & Bai, L. (2024) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2023-0448tr · Cited by 2
Mana, A. F. A., Culp, K., Keeler, A., Perrera, O., Rajagopalan, M. R., Jacky, L., Brown, B., & Thyagarajan, B. (2024) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-024-00732-y · Cited by 2
Takeda, H., Yamamoto, H., Oikawa, R., Umemoto, K., Arai, H., Mizukami, T., Ogawa, K., Uchida, Y., Nagata, Y., Kubota, Y., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.23.00425 · Cited by 3
Zeng, Y., Huang, C., Hou, Q., Jiang, W., Cheng, J., & Wu, X. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107833 · Cited by 3
ERK-dependent protein phosphorylation in KRAS-mutant cancer: a mix of the expected and surprising
Huang, K., Wang, Y., & Roberts, T. M. (2024) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2024.10.011 · Cited by 2
Melosky, B. L., Juergens, R. A., Banerji, S. O., Sacher, A. G., Wheatley‐Price, P., Snow, S. L., Tsao, M., Leighl, N. B., Martins, I., Cheema, P. K., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241308784 · Cited by 2
Megid, R., Ribeiro, G., Gomes, I. N. F., Laus, A. C., Leal, L. F., da Silva, L. S., Ariwoola, A.-B. A., Dias, J. M., Reis, R. M., & Oliveira, R. J. D. S. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1537523 · Cited by 3
Gaeta, B., Eichholz, J., Walch, H. S., Ilıca, A. T., Boe, L. A., Kratochvil, L. B., Yu, Y., Gomez, D. R., Imber, B. S., Li, B. T., et al. (2025) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2025.01.033 · Cited by 2
Klußmann, M., Reuter, J., Werner, C., & Neundorf, I. (2025) · Journal of Peptide Science · doi:10.1002/psc.70009 · Cited by 2
Liu, J., Wang, H., Aggarwal, A., Ortiz-Ruiz, M. J., Zapatero‐Solana, E., Lallena, M. J., Peregrina, S., del Hoyo, G. M., Velasco, S., Ebert, P. J., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1461530 · Cited by 2
Anticancer drug therapy for anaplastic thyroid cancer
Kiyota, N., Koyama, T., & Sugitani, I. (2025) · European Thyroid Journal · doi:10.1530/etj-24-0287 · Cited by 6
Treating KRAS G12C lung cancer: therapeutic potential of investigation drugs in early clinical study
Wilson, K., Banda, J. S. F., Raza, F., Bukkapatnam, S., Gangane, S., & Massarelli, E. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2511175 · Cited by 2
Wen, J., Dong, Y., Chen, T., Wu, J., Zhong, Y., Xu, L., Si, H., Huang, S., Hou, L., She, Y., et al. (2025) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2025.04.040 · Cited by 2
Danese, M. D., Shafrin, J. T., Laurie, M., Korytowsky, B., Jordan, S., Ryan, D., & Padda, S. K. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.07.019 · Cited by 2
Personalized therapy in metastatic colorectal cancer: biomarker-driven use of biologics
Sullo, F. G., Gallio, C., Matteucci, L., Bittoni, A., Muratore, M., Esposito, L., Ceredi, B., Gallo, G., Ulivi, P., Rapposelli, I. G., et al. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2556911 · Cited by 3
Evaluating the intracranial activity of adagrasib
Kotecha, R. R., Rosa, A. L., Kütük, T., Ahluwalia, M. S., & Mehta, M. P. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-74 · Cited by 2
Clerk, A., Amadi, S. U., Smith, S. J., & Sugden, P. H. (2024) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2024.100006 · Cited by 2
Editorial: Insights in head and neck cancer: 2021
Lybaert, W., & Vermorken, J. B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1180965 · Cited by 2
Arora, N., Hong, L., Kattan, W., Yao, W., Ying, H., Liu, J., & Zhou, Y. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.30.596653 · Cited by 2
Rappaport, J., Chen, Q., McGuire, T., Lopès, A., & Goldszmid, R. S. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.21.608131 · Cited by 2
Özakıncı, H., Desai, B., Kalos, D., Chen, D., Henry, M., Solanki, H. S., Boyle, T. A., Bittar, H. E. T., Nazario, G. S., Haura, E. B., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.17.628751 · Cited by 2
RAS mutation-specific signaling dynamics in response to paralog- and state- selective RAS inhibitorsPreprint
Baars, B., Orive-Ramos, A., Kou, Z., Gaire, B., Desaunay, M., Adamopoulos, C., Aaronson, S. A., Wang, S., Gavathiotis, E., & Poulikakos, P. I. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.02.14.638317 · Cited by 2
Genetic mechanisms of resistance to targeted KRAS inhibitionPreprint
Diaz, B. J., Kops, M. S., Bernardo, S., Schmidt, H., Grankowsky, E., Vega, A., Zhang, C., Bott, M. J., Skamagki, M., Tomlinson, A. C. A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.04.668444 · Cited by 2
Adaptive Feedback Signaling Through the FAK/SRC Pathway Promotes KRAS G12C Inhibitor Resistance
Udagawa, H., Shibata, Y., Nilsson, M. B., Nishii, K., Robichaux, J. P., Galan-Cobo, A., He, J., Poteete, A., Qian, Y., Molkentine, D., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103991 · Cited by 1
Self-citationPeng, S., Zhang, Y., Lin, X., Si, C., Van Horn, R. D., Dempsey, J. A., Goetz, E., Evans, R. J., Farber, A., Vandekopple, M. J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72650-y · Cited by 1
Self-citationEfficacy of chemoimmunotherapy in a lung adenocarcinoma patient with mutations in the KRAS and STK11
Krzyżanowska, N., Krawczyk, P. A., Chmielewska, I., Jankowski, T., Wojas‐Krawczyk, K., & Milanowski, J. (2023) · Oncology in Clinical Practice · doi:10.5603/ocp.2023.0012 · Cited by 1
Divide and conquer: towards isoform-specific diagnosis and therapy of KRAS-mutant lung cancer
Allemann, A., & Gautschi, O. P. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-72 · Cited by 1
Co-Occurrence of ALK rearrangement and KRAS G12C mutation in NSCLC: Report of two cases
Siringo, M., Larocca, F., Spagnuolo, A., Gentile, G., Anile, M., Diso, D., Santini, D., & Gelibter, A. J. (2024) · Current Problems in Cancer Case Reports · doi:10.1016/j.cpccr.2024.100291 · Cited by 1
Young, R. W. C., Rodriguez, G. R., Kucera, J. A., Carrera, D., Antevil, J. L., & Trachiotis, G. D. (2024) · Journal of Laparoendoscopic & Advanced Surgical Techniques · doi:10.1089/lap.2024.0164 · Cited by 1
Systemic Therapy for Metastatic Colon Cancer: New Frontiers
Pumpalova, Y. S. (2024) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0044-1787826 · Cited by 2
GOT2: New therapeutic target in pancreatic cancer
Bu, J., Miao, Z., & Yang, Q. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101370 · Cited by 1
Advancements in non-small cell lung cancer treatment: from early to advanced stages
Płużański, A., & Piórek, A. (2024) · Oncology in Clinical Practice · doi:10.5603/ocp.100477 · Cited by 1
Yang, X., Zhang, S., Yang, Y., Duan, X., & Li, X. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241264853 · Cited by 1
Eleftheriadou, E., Saroglou, M., Syrigos, N. K., Kotteas, E., & Kouvela, M. (2024) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2024.2967 · Cited by 1
Metadata
- Authors
- Jänne, P. A., Riely, G. J., Gadgeel, S. M., Heist, R. S., Ou, S.-H. I., Pacheco, J. M., Johnson, M. L., Sabari, J. K., Leventakos, K., Yau, E., Bazhenova, L., Negrao, M. V., Pennell, N. A., Zhang, J., Anderes, K., Der-Torossian, H., Kheoh, T., Velastegui, K., Yan, X., Christensen, J. G., Chao, R. C., & Spira, A. I.
- Affiliations
- From the Lowe Center for Thoracic Oncology, Dana–Farber Cancer Institute (P.A.J.), and Massachusetts General Hospital (R.S.H.) — both in Boston; the Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College (G.J.R.), and Perlmutter Cancer Center, New York University Langone Health (J.K.S.), New York, and the Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo (E.Y.) — all in New York; the Henry Ford Cancer Institute, Detroit (S.M.G.); the University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange (S.-H.I.O.), the University of California San Diego Moores Cancer Center, La Jolla (L.B.), and Mirati Therapeutics, San Diego (K.A., H.D.-T., T.K., K.V., X.Y., J.G.C., R.C.C.) — all in California; the Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora (J.M.P.); Sarah Cannon Research Institute at...
- Roswell Park Comprehensive Cancer Center (US)
- ORCID
- Riely, Gregory J.
- Gadgeel, Shirish M.
- Heist, Rebecca S.
- Ou, Sai-Hong I.
- Johnson, Melissa L.
- Sabari, Joshua K.
- Leventakos, Konstantinos
- Yau, Edwin
- Bazhenova, Lyudmila
- Negrao, Marcelo V.
- Pennell, Nathan A.
- Zhang, Jun
- Anderes, Kenna
- Kheoh, Thian
- Velastegui, Karen
- Christensen, James G.
- Chao, Richard C.
- Spira, Alexander I.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-14
- Volume
- 387
- Issue
- 2
- Pages
- 120-131
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281650778
- Cited by
- 1,061
- References
- 27
- Citations by year
- 2026: 247 · 2025: 270 · 2024: 285 · 2023: 203 · 2022: 56
- FWCI
- 131.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Mirati Therapeutics, Inc.
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- adagrasib, KRAS G12C mutation, non-small cell lung cancer, KRAS inhibitors, objective response rate, progression-free survival, overall survival, central nervous system metastasis, treatment-related adverse events, previously treated patients
- MeSH terms
- Acetonitriles, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Mutation, Piperazines, Pyrimidines, Proto-Oncogene Proteins p21(ras)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
